Trials / Completed
CompletedNCT00463268
Osteoporosis Prevention With Low Dose Alendronate
Prevention of Postmenopausal Bone Loss in Osteopenic Women With Alendronate Given on a 70 mg Once-every Two Week Regimen: a 2-year, Double-blind, Placebo-controlled Clinical Trial.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 83 (actual)
- Sponsor
- University Hospital of Mont-Godinne · Academic / Other
- Sex
- Female
- Age
- 45 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of the intermittent administration of alendronate in a low dose, 70 mg once every two week, as osteoporosis prevention for menopausal, osteopenic patients, who don't want or can't receive an oestrogenic substitution treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | alendronate | alendronate 70 mg every 2 weeks |
| DIETARY_SUPPLEMENT | Calcium/Vitamin D | Calcium 500 mg and vitamin D supplementation according to serum level |
| DRUG | placebo | identical placebo every 2 weeks |
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2012-01-01
- Completion
- 2012-01-01
- First posted
- 2007-04-20
- Last updated
- 2013-05-29
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT00463268. Inclusion in this directory is not an endorsement.